tirzepatide surmount-1 weight loss percent 72 weeks results SURMOUNT-1: In an RCT, adults with obesity treated with weekly had major over weeks. #ADA2022 https://t.co/X2RrvYxzsV Tirzepatide for the Maintenance of

Replace the pen cap and store the pen as directed in your patient information leaflet

The primary outcome was resolution of MASH without worsening of fibrosis at 52 weeks as determined by liver biopsy (Fig

People with a personal or family history of MTC, or a rare endocrine condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), should avoid using this medication

It can help to restore circadian rhythm and regulates the cell cycle

SAVOR-TIMI 53 steering committee and investigators *

It also provides guidelines for healthcare providers on monitoring and adjusting treatment to optimize patient outcomes